All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.

The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your Multiple Myeloma Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
2020-10-23T07:57:21.000Z

Second part of the phase III CASSIOPEIA study meets its primary endpoint

Oct 23, 2020
Share:

Bookmark this article

Positive topline results from the second part of the phase III CASSIOPEIA (NCT02541383) study were announced on October 21, 2020.

The first part of the CASSIOPEIA study aimed to compare daratumumab (Dara), an anti-CD38 antibody, plus bortezomib (V), thalidomide (T), and dexamethasone (d) versus VTd alone in 1,085 transplant-eligible patients with newly diagnosed multiple myeloma. The quadruplet was well tolerated and provided significant clinical benefit compared with VTd in this population of patients (read the full results here).

The second part of the study evaluated Dara as maintenance treatment (16 mg/kg every 8 weeks, for up to 2 years) versus no treatment (observation) in patients who achieved a response; the primary endpoint of this second part was progression-free survival (PFS).

This second part met its primary endpoint of improving PFS at a pre-planned interim analysis (HR, 0.53; 95% CI, 0.42–0.68; p < 0.0001), with a reduction in the risk of progression or death in patients who received Dara of 47%. The safety profile was consistent with the known Dara safety profile.

  1. Genmab announces IFM, HOVON and Janssen achieve positive topline results in second part of phase 3 cassiopeia study of daratumumab in multiple myeloma at pre-planned interim analysis. https://ir.genmab.com/news-releases/news-release-details/genmab-announces-ifm-hovon-and-janssen-achieve-positive-topline. Published Oct 21, 2020. Accessed Oct 22, 2020.

Newsletter

Subscribe to get the best content related to multiple myeloma delivered to your inbox